Start Your Free Review
Answer 2-3 quick questions to review your potential case.
Pfizer's $430 Million Off-Label Promotion Scheme
In 2004, Warner-Lambert (acquired by Pfizer in 2000) pleaded guilty to two federal felony counts of violating the Food, Drug, and Cosmetic Act by promoting gabapentin (marketed as Neurontin) for unapproved uses. The company paid $430 million — $240 million in criminal fines and $190 million to settle civil False Claims Act allegations. Federal prosecutors proved that Warner-Lambert had implemented a systematic campaign to promote Neurontin for at least eleven unapproved conditions, including migraine prevention, bipolar disorder, pain management, attention deficit disorder, restless leg syndrome, drug and alcohol withdrawal, and other conditions for which the drug had no FDA-approved indication.
Internal company documents revealed that Warner-Lambert paid physicians to attach their names to ghostwritten articles promoting off-label uses, funded sham advisory boards and speaker programs to disseminate off-label messaging, planted favorable articles in medical literature through publication planning firms, and trained sales representatives to proactively promote unapproved uses in physician offices. The company's own projections estimated that off-label uses would generate the majority of Neurontin revenue — a prediction that proved accurate as off-label prescribing came to dominate the drug's market. Despite the criminal conviction, Pfizer never undertook the clinical trials necessary to establish safety and efficacy for these off-label uses, including comprehensive cognitive safety testing in the populations now receiving the drug.
The 80 Percent Off-Label Reality
Gabapentin's FDA-approved indications are narrow: postherpetic neuralgia (shingles pain) in adults and adjunctive therapy for partial seizures in patients aged 3 and older. Yet studies consistently show that 83 to 95 percent of gabapentin prescriptions are written for off-label purposes. The most common off-label uses include general neuropathic pain, lower back pain, fibromyalgia, migraine prevention, anxiety disorders, insomnia, alcohol use disorder, and various other chronic pain conditions. For many of these uses, the clinical evidence supporting gabapentin's efficacy is weak or nonexistent — a Cochrane review found that gabapentin is ineffective for low back pain, and trials for fibromyalgia have shown modest benefit at best.
The off-label prescribing explosion was further fueled by the opioid crisis. As regulators, insurers, and medical boards pressured physicians to reduce opioid prescribing beginning around 2016, gabapentin emerged as a convenient alternative — perceived as non-addictive (a claim now disputed), inexpensive as a generic, and broadly tolerated. This massive shift in prescribing patterns occurred without adequate safety surveillance or clinical trials demonstrating gabapentin's cognitive safety profile in the expanded patient populations now receiving the drug. Millions of Americans were prescribed gabapentin for pain conditions where it had no proven efficacy and unknown cognitive risks.
How Off-Label Prescribing Amplifies Cognitive Risk
When a drug is prescribed off-label, the informed consent process is fundamentally compromised. For FDA-approved indications, the prescribing information provides detailed safety data drawn from clinical trials conducted in the relevant patient population. For off-label uses, no such population-specific safety data exists. Patients prescribed gabapentin for chronic back pain, anxiety, or insomnia cannot be properly informed about their cognitive risk because that risk has never been formally studied in their population. They consent to treatment based on incomplete information, a situation created by the manufacturer's decision to market the drug for unapproved uses without pursuing the clinical trials necessary to characterize safety.
Furthermore, off-label uses often involve higher doses and longer treatment durations than FDA-approved indications. Postherpetic neuralgia, the primary approved use, is typically a self-limiting condition lasting months to a few years, whereas off-label uses like chronic back pain or fibromyalgia are lifelong conditions that result in decades of continuous gabapentin exposure. The 2025 JAMA Internal Medicine study found that duration of use was a significant risk factor for cognitive decline, meaning off-label patients with chronic conditions face the longest exposures and greatest cumulative cognitive risk.
Legal Theories for Off-Label Prescribing Claims
Patients who developed cognitive decline or dementia after off-label gabapentin use have multiple legal theories available. Failure-to-warn claims argue that the manufacturer knew or should have known about cognitive risks in off-label populations and failed to update labeling accordingly. Negligent marketing claims target the manufacturer's creation of an off-label market through illegal promotion without conducting the safety studies needed to protect those patients. Fraud-based claims can draw on the 2004 criminal conviction to establish a pattern of prioritizing revenue over safety.
The 2004 guilty plea and $430 million settlement provide powerful evidence that the manufacturer knowingly created the off-label market. Under the learned intermediary doctrine — which normally shields manufacturers by placing prescribing responsibility on physicians — the manufacturer's illegal off-label promotion undermined physicians' independent judgment by corrupting the medical literature and paying opinion leaders to recommend unapproved uses. This corruption of the prescribing chain creates liability that bypasses the traditional learned intermediary defense and reaches the manufacturer directly.
Prescribing Volume and the Scope of Harm
The scale of gabapentin off-label prescribing translates to a massive population at risk for cognitive harm. With over 70 million prescriptions dispensed annually and the majority written for unapproved uses, tens of millions of Americans have been exposed to cognitive risks that were never formally evaluated. Gabapentin ranked as the sixth most prescribed drug in the United States in 2022. Geographic analysis shows highest per-capita prescribing in states with elevated chronic pain prevalence and opioid crisis impact — regions like Appalachia, the rural South, and the Midwest where alternative pain management resources are scarce and patients often have limited access to specialist care that might catch early cognitive decline.
The economic implications are staggering. If even a small percentage of the millions of off-label gabapentin users develop measurable cognitive decline, the aggregate healthcare costs — neurological evaluations, cognitive rehabilitation, premature assisted living placement, lost productivity — run into the billions. This economic reality, combined with the documented criminal history of off-label promotion, positions gabapentin cognitive decline litigation as one of the most significant emerging mass tort actions in pharmaceutical law.
Evidence Preservation for Off-Label Claims
Patients pursuing off-label gabapentin claims should gather evidence demonstrating that their prescription was for an unapproved use. Medical records showing the diagnosis or condition for which gabapentin was prescribed are essential. If the prescribing physician documented the indication as anything other than postherpetic neuralgia or epilepsy, the off-label nature of the prescription is established. Pharmacy records, insurance claim forms with diagnosis codes, and office visit notes all contribute to this documentation. Evidence that the prescribing physician received payments, meals, or speaking fees from Pfizer or gabapentin generic manufacturers — searchable through the CMS Open Payments database — can strengthen claims of manufacturer influence on the prescribing decision.
Frequently Asked Questions
Related Pages
Gabapentin Cognitive Decline & Memory Loss
Gabapentin-induced cognitive decline is an underrecognized but increasingly documented adverse effect that manifests as persistent memory loss, executive function impairment, concentration difficulties, and a pervasive mental fog that patients describe as feeling like thinking through cotton. A landmark 2025 retrospective cohort study published in JAMA Internal Medicine found that gabapentin users faced a 1.58-fold increased risk of dementia and a 2.73-fold increased risk of mild cognitive impairment compared to non-users, with risk escalating at doses above 900 mg daily. The mechanism involves gabapentin binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, disrupting synaptic plasticity and long-term potentiation — the neurological processes essential for memory formation and retrieval. Unlike age-related cognitive decline that progresses gradually over years, gabapentin-induced impairment often emerges within months of dose escalation and can affect patients as young as their thirties. Distinguishing gabapentin-caused cognitive decline from natural aging or early Alzheimer's disease is critical for both medical treatment and legal claims, as the pharmaceutical industry has systematically downplayed these cognitive risks while promoting gabapentin for an ever-expanding list of off-label uses.
Gabapentin Risks for Elderly Patients
Elderly patients aged 65 and older face dramatically amplified gabapentin cognitive risks due to age-related decline in renal function that causes the drug to accumulate to dangerous levels in the body and brain. Because gabapentin is eliminated almost entirely through the kidneys, even a modest reduction in glomerular filtration rate — which occurs naturally with aging — can double or triple effective blood concentrations at standard doses. The Beers Criteria, published by the American Geriatrics Society, has flagged gabapentin as potentially inappropriate for older adults, yet prescribing to this population has surged as physicians seek opioid alternatives for chronic pain management in the elderly. Polypharmacy compounds the danger: elderly patients taking gabapentin alongside benzodiazepines, opioids, or anticholinergic medications face multiplicative CNS depression and cognitive impairment. Perhaps most insidiously, gabapentin-induced cognitive decline in elderly patients is routinely misattributed to normal aging or early Alzheimer's disease, leading to years of unnecessary cognitive deterioration while the true cause — a preventable pharmaceutical injury — goes unrecognized and untreated.
Gabapentin Withdrawal & Tapering Risks
Gabapentin withdrawal is a medically serious and legally significant condition that can produce seizures, severe anxiety, insomnia, nausea, pain rebound, and cognitive disruption — symptoms that Pfizer and subsequent manufacturers have historically downplayed by marketing gabapentin as non-addictive and easy to discontinue. The reality is starkly different: gabapentin produces physical dependence in a significant portion of long-term users, and abrupt discontinuation can trigger withdrawal seizures even in patients with no history of epilepsy. The FDA's prescribing information warns against abrupt discontinuation and recommends tapering over at least one week, yet this guidance is frequently inadequate for patients who have used the drug at high doses for extended periods. Withdrawal complications create a cruel dilemma for patients who learn about gabapentin's cognitive risks: they cannot safely stop the drug without medical supervision, and the tapering process itself can take weeks to months, during which they continue to accumulate cognitive exposure. For patients already experiencing gabapentin-induced cognitive decline, the withdrawal period adds additional neurological insult and extends the window of harm. The manufacturer's failure to adequately warn about dependence potential and withdrawal severity constitutes a distinct basis for legal liability, separate from but complementary to cognitive decline claims.
Gabapentin & Early-Onset Dementia in Young Adults
The most alarming finding in the 2025 JAMA Internal Medicine gabapentin study was the disproportionate cognitive risk among younger adults. In the 35-to-49 age group, gabapentin users experienced a doubling of dementia incidence and a tripling of mild cognitive impairment compared to non-users — effects that were proportionally larger than those seen in older populations. Early-onset dementia in working-age adults is a catastrophic injury that destroys careers, fractures families, eliminates independence, and imposes decades of care costs that far exceed those in elderly-onset cases. These patients are typically prescribed gabapentin for chronic pain conditions including fibromyalgia, migraines, or workplace injuries, often at high doses for years or decades. Because dementia is not expected in a 40-year-old, the gabapentin connection may go unrecognized for years while the patient loses employment, relationships, and financial stability. The economic damages in young-adult gabapentin dementia cases are among the highest in pharmaceutical litigation, encompassing 20 to 30 years of lost earning capacity, lifetime care costs potentially exceeding $3 million, and the profound non-economic losses of a life fundamentally derailed during what should be its most productive years.
Gabapentin Dementia Lawsuit Lawsuit
Gabapentin (brand name Neurontin) is one of the most widely prescribed medications in America, dispensed more than 67 million times annually — yet the majority of those prescriptions are for uses the FDA never approved. Originally indicated for epilepsy and postherpetic neuralgia, gabapentin has been massively promoted for chronic pain, anxiety, insomnia, and dozens of other off-label conditions. A July 2025 population-level study now links chronic gabapentin use to significant increases in dementia and mild cognitive impairment, with younger patients facing the steepest risk elevations. Pfizer's subsidiary Warner-Lambert already paid $430 million in 2004 for systematically promoting gabapentin for off-label uses. Litigation is now emerging on behalf of patients who developed cognitive decline after long-term gabapentin use without adequate warnings about neurodegenerative risk.
View full case overview